Arovella Therapeutics Ltd has released a press release.
ZolpiMist Clinical Results Published
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- European Anagrelide Cancer Patent
- Supplementary Prospectus
- Rights Issue Closes Significantly Oversubscribed
- SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
- Prospectus For Renounceable Pro Rata Offer
Later from Arovella Therapeutics
- ArTiMist Appeal Lodged With TGA
- Manaing Director and CEO Resignation
- Response to ASX Query regarding Accounts
- SUDA Finalises Agreement With Cann Pharmaceutical
- Case For Share Consolidation and Appendix 3A.3
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics